---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-109860"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:22:24.596975+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics Q3 net loss $3.0M; cash runway into Q4 2026; clinical updates on APR-1051 and ATRN-119

## Summary
- Cash and cash equivalents $13.7M as of Sep 30, 2025; operating loss $3.1M vs $4.1M YoY.
- Net loss $3.0M ($0.47 per basic share) on 6.4M weighted avg shares; R&D expenses $1.6M.
- APR-1051 Phase 1: 3 of 4 patients at 100mg QD achieved stable disease; dose escalation advanced to 150mg.
- ATRN-119: RP2D set at 1,100mg QD; enrollment paused to explore combination studies with radiation.
- Cash sufficient into Q4 2026; anticipates value-creating catalysts in 2026.

## SEC filing metadata
- accession: 0001104659-25-109860
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465925109860/0001104659-25-109860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465925109860/apre-20251112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-109860
- JSON: https://secwatch.observer/filing/0001104659-25-109860.json
- Plain text: https://secwatch.observer/filing/0001104659-25-109860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.